Maria Ekholm

MD, PhD, Associate professor

Linköping University

Sweden

Research Interests

Explore related searches

Professors in Sweden Professors in Immunology Immunology professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Maria Ekholm, MD, PhD, is an Associate Professor at Linköping University in Sweden. Her research primarily focuses on breast cancer, including the evaluation of chemotherapy responses, prognostic biomarkers, and treatment benefits for premenopausal patients. Recent publications explore patients' experiences with metronomic chemotherapy and the predictive value of tumor-infiltrating lymphocytes in treatment outcomes.

Articles (11)

Year:

2025

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (11)

Fredrik Wärnberg

Professor breast surgery

Karolinska University Hospital

SWEDEN

View details

Lisa Rydén

Professor Surgery

Umeå Universitet Medicinska fakulteten

SWEDEN

View details

Ewa Grzybowska

Professor

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

Roger Olofsson Bagge

Professor

University of Gothenburg

SWEDEN

View details

Julia Tutzauer

Karolinska Institutet

SWEDEN

View details

Mårten Fernö

Professor

Lund University Medical Faculty Foundation

SWEDEN

View details

Balazs Acs

Karolinska Institutet

SWEDEN

View details

Laura Woodhouse

The University of Manchester

UNITED KINGDOM

View details

Johan Hartman

Professor at Karolinska Institutet

Karolinska Institutet

SWEDEN

View details

Theodoros Foukakis

Karolinska Institutet

SWEDEN

View details

Per Karlsson

University of Gothenburg

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Maria Ekholm

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Convenient but concerning: patients' experiences of metronomic chemotherapy in metastatic breast cancer

Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit

Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study

PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study

Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer

Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.

Survival from breast cancer in women with a BRCA2 mutation by treatment.

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer.

Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)

Collaborators (11)

Fredrik Wärnberg

Lisa Rydén

Ewa Grzybowska

Roger Olofsson Bagge

Julia Tutzauer

Mårten Fernö

Balazs Acs

Laura Woodhouse

Johan Hartman

Theodoros Foukakis

Per Karlsson

Make your next move.